Compared to the control group (Dox−), Dox+ significantly induced TCP1 knockdown in tumor tissues and reduced tumor volume (Figure 2E–G), which further verified that targeting TCP1 could be a potential treatment option for AML. Here, TCP1 is linked to acute myeloid leukemia.